A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line Treatment
RIBANNA
1 other identifier
observational
2,610
1 country
265
Brief Summary
This is a non-interventional observational study conducted in Germany to evaluate the real-world effectiveness, tolerability, safety, and quality of life in patients with locally advanced/metastatic HR+/HER2- breast cancer treated with one of the following 1st line treatments: Ribociclib + AI/FUL, or endocrine monotherapy, or chemotherapy
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2017
Longer than P75 for all trials
265 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 9, 2017
CompletedFirst Submitted
Initial submission to the registry
December 29, 2023
CompletedFirst Posted
Study publicly available on registry
March 15, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 10, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
March 10, 2025
CompletedJanuary 27, 2026
January 1, 2026
7.4 years
December 29, 2023
January 23, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Progression-free survival (PFS)
Progression-free survival was defined as first intake of study medication in current-line therapy up to first documented progress or death from any cause in this treatment line. If a patient had not had an event, progression-free survival was censored at the end of the respective therapy line.
Up to 88 months
Secondary Outcomes (13)
Sequential progression-free survival (PFS_S)
Up to 88 months
Time to treatment failure (TTF)
Up to 88 months
Time to first chemotherapy
Up to 88 months
Time to next treatment / therapy (TTNT) after 1st line treatment
Up to 88 months
Overall survival (OS)
Up to 88 months
- +8 more secondary outcomes
Study Arms (3)
First-line Ribociclib + endocrine therapy
Ribociclib + letrozole, or Ribociclib + anastrozole, or Ribociclib + exemestane, or Ribociclib + fulvestrant
First-line endocrine therapy
As of physicians choice
First-line chemotherapy
As of physicians choice
Interventions
Ribociclib + letrozole, or Ribociclib + anastrazole, or Ribociclib + exemestane, or Ribociclib + fulvestrant
Eligibility Criteria
Adult females with HR+/HER2- locally advanced/metastatic breast cancer (progressed following prior therapy or de novo). Hereby locally advanced is defined by the following criteria (at least one must apply): tumor size \> 5 cm (T3), skin or chest wall infiltration (T4a, T4b), inflammatory breast cancer (T4c), fixed axilla-located lymph node conglomerate or intraclavicular lymph node metastasis (cN3; German S3 guideline for early detection, diagnosis, therapy and follow-up care of breast cancer; Version 4.1.2018). Patients are classified as therapy naïve for locally advanced/metastatic disease if they have not yet received a systemic therapy in the palliative setting. Patients with locally advanced breast cancer who have received therapy-(lines) in the adjuvant/curative setting are eligible after progression to e.g. a metastatic breast cancer. All patients who already received a palliative therapy for locally advanced/metastatic breast cancer are excluded from study participation.
You may qualify if:
- Patients with a histological diagnosis of locally advanced/metastatic HR+/HER2- breast cancer. Histological diagnosis does not necessarily origin from metastasis, but must reflect the most recent disease status
- No prior systemic treatment for locally advanced/metastatic disease in the palliative setting
- The treating physician has made the decision to treat the patient
- with ribociclib in combination with an aromatase inhibitor or fulvestrant as initial treatment in first line, or
- endocrine therapy as initial treatment in first line (e.g. letrozole, anastrozole, fulvestrant), or
- chemotherapy as initial treatment in first line (e.g. taxanes, capecitabine, with or without bevacizumab)
- Written informed consent of the patient
- Patient who initiated treatment for first line no longer than 4 weeks (28 days) prior to written informed consent for this study
- Planned treatment is in line with the respective current German SmPC ("Summary of product characteristics")
- Patient is ≥18 years
You may not qualify if:
- Patients unable to provide written informed consent
- Contra-indication according to the respective current German SmPC ("Summary of product characteristics"), as judged by the treating physician
- The patient is currently under active treatment in an investigational study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (265)
Novartis Investigative Site
Baden-Baden, Baden-Wurttemberg, 76532, Germany
Novartis Investigative Site
Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany
Novartis Investigative Site
Freudenstadt, Baden-Wurttemberg, 72250, Germany
Novartis Investigative Site
Heidenheim, Baden-Wurttemberg, 89522, Germany
Novartis Investigative Site
Karlsruhe, Baden-Wurttemberg, 76199, Germany
Novartis Investigative Site
Mannheim, Baden-Wurttemberg, 68161, Germany
Novartis Investigative Site
Mannheim, Baden-Wurttemberg, 68165, Germany
Novartis Investigative Site
Mutlangen, Baden-Wurttemberg, 73557, Germany
Novartis Investigative Site
Nürtingen, Baden-Wurttemberg, 72622, Germany
Novartis Investigative Site
Ostfildern, Baden-Wurttemberg, 73760, Germany
Novartis Investigative Site
Pforzheim, Baden-Wurttemberg, 75175, Germany
Novartis Investigative Site
Reutlingen, Baden-Wurttemberg, 72764, Germany
Novartis Investigative Site
Rottweil, Baden-Wurttemberg, 78628, Germany
Novartis Investigative Site
Schwäbisch Hall, Baden-Wurttemberg, 74523, Germany
Novartis Investigative Site
Sigmaringen, Baden-Wurttemberg, 72488, Germany
Novartis Investigative Site
Winnenden, Baden-Wurttemberg, 71364, Germany
Novartis Investigative Site
Altötting, Bavaria, 84503, Germany
Novartis Investigative Site
Amberg, Bavaria, 92224, Germany
Novartis Investigative Site
Ansbach, Bavaria, 91522, Germany
Novartis Investigative Site
Aschaffenburg, Bavaria, 63739, Germany
Novartis Investigative Site
Augsburg, Bavaria, 86152, Germany
Novartis Investigative Site
Bamberg, Bavaria, 96052, Germany
Novartis Investigative Site
Bayreuth, Bavaria, 95445, Germany
Novartis Investigative Site
Donauwörth, Bavaria, 86609, Germany
Novartis Investigative Site
Ebersberg, Bavaria, 85560, Germany
Novartis Investigative Site
Eggenfelden, Bavaria, 84307, Germany
Novartis Investigative Site
Kempten (Allgäu), Bavaria, 87439, Germany
Novartis Investigative Site
Kronach, Bavaria, 96317, Germany
Novartis Investigative Site
Krumbach, Bavaria, 86381, Germany
Novartis Investigative Site
Landshut, Bavaria, 84036, Germany
Novartis Investigative Site
Munich, Bavaria, 80639, Germany
Novartis Investigative Site
Munich, Bavaria, 81241, Germany
Novartis Investigative Site
Munich, Bavaria, 81925, Germany
Novartis Investigative Site
Nuremberg, Bavaria, 90409, Germany
Novartis Investigative Site
Regensburg, Bavaria, 93053, Germany
Novartis Investigative Site
Straubing, Bavaria, 94315, Germany
Novartis Investigative Site
Würzburg, Bavaria, 97070, Germany
Novartis Investigative Site
Würzburg, Bavaria, 97080, Germany
Novartis Investigative Site
Mannheim, Beden Wuerttenberg, 68167, Germany
Novartis Investigative Site
Brandenburg, Brandenburg, 14770, Germany
Novartis Investigative Site
Cottbus, Brandenburg, 03048, Germany
Novartis Investigative Site
Doberlug-Kirchhain, Brandenburg, 03253, Germany
Novartis Investigative Site
Fürstenwalde, Brandenburg, 15517, Germany
Novartis Investigative Site
Ludwigsfelde, Brandenburg, 14974, Germany
Novartis Investigative Site
Spremberg, Brandenburg, 03130, Germany
Novartis Investigative Site
Bremen, City state Bremen, 28209, Germany
Novartis Investigative Site
Bremen, City state Bremen, 28239, Germany
Novartis Investigative Site
Bremerhaven, City state Bremen, 27576, Germany
Novartis Investigative Site
Schwerte, Germany, 58239, Germany
Novartis Investigative Site
Wiesbaden, Germany, 65191, Germany
Novartis Investigative Site
Hamburg, Hamburg, 22087, Germany
Novartis Investigative Site
Hamburg, Hamburg, 22291, Germany
Novartis Investigative Site
Hamburg, Hamburg, 22457, Germany
Novartis Investigative Site
Bad Homburg, Hesse, 61352, Germany
Novartis Investigative Site
Bad Nauheim, Hesse, 61231, Germany
Novartis Investigative Site
Darmstadt, Hesse, 64283, Germany
Novartis Investigative Site
Erbach im Odenwald, Hesse, 64711, Germany
Novartis Investigative Site
Frankfurt am Main, Hesse, 60398, Germany
Novartis Investigative Site
Frankfurt am Main, Hesse, 60431, Germany
Novartis Investigative Site
Frankfurt am Main, Hesse, 65929, Germany
Novartis Investigative Site
Langen, Hesse, 63225, Germany
Novartis Investigative Site
Lich, Hesse, 35423, Germany
Novartis Investigative Site
Marburg, Hesse, 35043, Germany
Novartis Investigative Site
Braunschweig, Lower Saxony, 38100, Germany
Novartis Investigative Site
Buchholz, Lower Saxony, 21244, Germany
Novartis Investigative Site
Damme, Lower Saxony, 49401, Germany
Novartis Investigative Site
Georgsmarienhütte, Lower Saxony, 49124, Germany
Novartis Investigative Site
Hamelin, Lower Saxony, 31785, Germany
Novartis Investigative Site
Hanover, Lower Saxony, 30171, Germany
Novartis Investigative Site
Hildesheim, Lower Saxony, 31134, Germany
Novartis Investigative Site
Ilsede, Lower Saxony, 31241, Germany
Novartis Investigative Site
Lingen Ems, Lower Saxony, 49808, Germany
Novartis Investigative Site
Osnabrück, Lower Saxony, 49076, Germany
Novartis Investigative Site
Rotenburg (Wümme), Lower Saxony, 27356, Germany
Novartis Investigative Site
Twistringen, Lower Saxony, 27239, Germany
Novartis Investigative Site
Westerstede, Lower Saxony, 26655, Germany
Novartis Investigative Site
Wolfenbüttel, Lower Saxony, 38304, Germany
Novartis Investigative Site
Neubrandenburg, Mecklenburg-Vorpommern, 17036, Germany
Novartis Investigative Site
Rostock, Mecklenburg-Vorpommern, 18057, Germany
Novartis Investigative Site
Schwerin, Mecklenburg-Vorpommern, 19059, Germany
Novartis Investigative Site
Stralsund, Mecklenburg-Vorpommern, 18435, Germany
Novartis Investigative Site
Arnsberg, North Rhine-Westphalia, 59759, Germany
Novartis Investigative Site
Bergisch Gladbach, North Rhine-Westphalia, 51465, Germany
Novartis Investigative Site
Bielefeld, North Rhine-Westphalia, 33611, Germany
Novartis Investigative Site
Bielefeld, North Rhine-Westphalia, 33615, Germany
Novartis Investigative Site
Bochum, North Rhine-Westphalia, 44787, Germany
Novartis Investigative Site
Bonn, North Rhine-Westphalia, 53113, Germany
Novartis Investigative Site
Bonn, North Rhine-Westphalia, 53177, Germany
Novartis Investigative Site
Cologne, North Rhine-Westphalia, 50179, Germany
Novartis Investigative Site
Cologne, North Rhine-Westphalia, 50937, Germany
Novartis Investigative Site
Dortmund, North Rhine-Westphalia, 44137, Germany
Novartis Investigative Site
Dortmund, North Rhine-Westphalia, 44309, Germany
Novartis Investigative Site
Düsseldorf, North Rhine-Westphalia, 40325, Germany
Novartis Investigative Site
Düsseldorf, North Rhine-Westphalia, 40625, Germany
Novartis Investigative Site
Gelsenkirchen, North Rhine-Westphalia, 45879, Germany
Novartis Investigative Site
Hagen, North Rhine-Westphalia, 58089, Germany
Novartis Investigative Site
Herdecke, North Rhine-Westphalia, 58313, Germany
Novartis Investigative Site
Herne, North Rhine-Westphalia, 44649, Germany
Novartis Investigative Site
Hilden, North Rhine-Westphalia, 40724, Germany
Novartis Investigative Site
Krefeld, North Rhine-Westphalia, 47805, Germany
Novartis Investigative Site
Lemgo, North Rhine-Westphalia, 32657, Germany
Novartis Investigative Site
Mönchengladbach, North Rhine-Westphalia, 41061, Germany
Novartis Investigative Site
Olpe, North Rhine-Westphalia, 57462, Germany
Novartis Investigative Site
Paderborn, North Rhine-Westphalia, 33098, Germany
Novartis Investigative Site
Remscheid, North Rhine-Westphalia, 42853, Germany
Novartis Investigative Site
Remscheid, North Rhine-Westphalia, 42859, Germany
Novartis Investigative Site
Siegen, North Rhine-Westphalia, 57072, Germany
Novartis Investigative Site
Troisdorf, North Rhine-Westphalia, 53840, Germany
Novartis Investigative Site
Velbert, North Rhine-Westphalia, 42551, Germany
Novartis Investigative Site
Wesel, North Rhine-Westphalia, 46483, Germany
Novartis Investigative Site
Wesel, North Rhine-Westphalia, 46485, Germany
Novartis Investigative Site
Witten, North Rhine-Westphalia, 58455, Germany
Novartis Investigative Site
Mayen, Rhineland-Palatinate, 56727, Germany
Novartis Investigative Site
Neustadt an der Weinstraße, Rhineland-Palatinate, 67434, Germany
Novartis Investigative Site
Simmern, Rhineland-Palatinate, 55469, Germany
Novartis Investigative Site
Lebach, Saarland, 66822, Germany
Novartis Investigative Site
Dresden, Saxony, 01127, Germany
Novartis Investigative Site
Dresden, Saxony, 01307, Germany
Novartis Investigative Site
Leipzig, Saxony, 04103, Germany
Novartis Investigative Site
Leipzig, Saxony, 04129, Germany
Novartis Investigative Site
Lohsa-Weisskollm, Saxony, 02999, Germany
Novartis Investigative Site
Neustadt in Sachsen, Saxony, 01844, Germany
Novartis Investigative Site
Pirna, Saxony, 01796, Germany
Novartis Investigative Site
Plauen, Saxony, 08525, Germany
Novartis Investigative Site
Rodewisch, Saxony, 08228, Germany
Novartis Investigative Site
Scheibenberg, Saxony, 09481, Germany
Novartis Investigative Site
Schkeuditz, Saxony, 04435, Germany
Novartis Investigative Site
Zittau, Saxony, 02763, Germany
Novartis Investigative Site
Zxickau, Saxony, 08060, Germany
Novartis Investigative Site
Halle, Saxony-Anhalt, 06110, Germany
Novartis Investigative Site
Magdeburg, Saxony-Anhalt, 39108, Germany
Novartis Investigative Site
Magdeburg, Saxony-Anhalt, 39130, Germany
Novartis Investigative Site
Quedlinburg, Saxony-Anhalt, 06484, Germany
Novartis Investigative Site
Flensburg, Schleswig-Holstein, 24939, Germany
Novartis Investigative Site
Lübeck, Schleswig-Holstein, 23563, Germany
Novartis Investigative Site
Berlin, State of Berlin, 10117, Germany
Novartis Investigative Site
Berlin, State of Berlin, 10317, Germany
Novartis Investigative Site
Berlin, State of Berlin, 13187, Germany
Novartis Investigative Site
Berlin, State of Berlin, 14197, Germany
Novartis Investigative Site
Apolda, Thuringia, 99510, Germany
Novartis Investigative Site
Eisenach, Thuringia, 99817, Germany
Novartis Investigative Site
Erfurt, Thuringia, 99084, Germany
Novartis Investigative Site
Jena, Thuringia, 07740, Germany
Novartis Investigative Site
Meiningen, Thuringia, 98617, Germany
Novartis Investigative Site
Mühlhausen, Thuringia, 99974, Germany
Novartis Investigative Site
Nordhausen, Thuringia, 99734, Germany
Novartis Investigative Site
Suhl, Thuringia, 98527, Germany
Novartis Investigative Site
Altötting, 84503, Germany
Novartis Investigative Site
Augsburg, 86150, Germany
Novartis Investigative Site
Augsburg, 86179, Germany
Novartis Investigative Site
Bad Liebenwerda, 04924, Germany
Novartis Investigative Site
Bamberg, 96049, Germany
Novartis Investigative Site
Bayreuth, 95445, Germany
Novartis Investigative Site
Berlin, 10715, Germany
Novartis Investigative Site
Berlin, 12487, Germany
Novartis Investigative Site
Berlin, 13353, Germany
Novartis Investigative Site
Berlin, 13581, Germany
Novartis Investigative Site
Berlin, 14169, Germany
Novartis Investigative Site
Bochum, 44791, Germany
Novartis Investigative Site
Bonn, 53111, Germany
Novartis Investigative Site
Bonn, 53113, Germany
Novartis Investigative Site
Bottrop, 46236, Germany
Novartis Investigative Site
Böblingen, 71032, Germany
Novartis Investigative Site
Brandenburg, 14770, Germany
Novartis Investigative Site
Bremen, 28205, Germany
Novartis Investigative Site
Bremerhaven, 27574, Germany
Novartis Investigative Site
Celle, 29223, Germany
Novartis Investigative Site
Chemnitz, 09113, Germany
Novartis Investigative Site
Chemnitz, 09117, Germany
Novartis Investigative Site
Cologne, 50671, Germany
Novartis Investigative Site
Cologne, 50935, Germany
Novartis Investigative Site
Cologne, 51067, Germany
Novartis Investigative Site
Dessau, 06847, Germany
Novartis Investigative Site
Dresden, 01307, Germany
Novartis Investigative Site
Erfurt, 99084, Germany
Novartis Investigative Site
Erlangen, 91054, Germany
Novartis Investigative Site
Essen, 45147, Germany
Novartis Investigative Site
Esslingen am Neckar, 73730, Germany
Novartis Investigative Site
Eutin, 23701, Germany
Novartis Investigative Site
Friedberg, 86316, Germany
Novartis Investigative Site
Friedrichshafen, 88045, Germany
Novartis Investigative Site
Gera, 07548, Germany
Novartis Investigative Site
Goch, 47574, Germany
Novartis Investigative Site
Goslar, 38642, Germany
Novartis Investigative Site
Göttingen, 37073, Germany
Novartis Investigative Site
Göttingen, 37075, Germany
Novartis Investigative Site
Greifswald, 17475, Germany
Novartis Investigative Site
Gummersbach, 51643, Germany
Novartis Investigative Site
Halberstadt, 38820, Germany
Novartis Investigative Site
Hamburg, 20259, Germany
Novartis Investigative Site
Hamburg, 20357, Germany
Novartis Investigative Site
Hamburg, 22081, Germany
Novartis Investigative Site
Hamelin, 31785, Germany
Novartis Investigative Site
Hanau, 63450, Germany
Novartis Investigative Site
Hanover, 30161, Germany
Novartis Investigative Site
Hanover, 30177, Germany
Novartis Investigative Site
Hanover, 30625, Germany
Novartis Investigative Site
Hof, 95028, Germany
Novartis Investigative Site
Homburg, 66421, Germany
Novartis Investigative Site
Kaiserslautern, 67655, Germany
Novartis Investigative Site
Karlsruhe, 76133, Germany
Novartis Investigative Site
Karlsruhe, 76135, Germany
Novartis Investigative Site
Kassel, 34119, Germany
Novartis Investigative Site
Kiel, 24105, Germany
Novartis Investigative Site
Koblenz, 56068, Germany
Novartis Investigative Site
Kulmbach, 95326, Germany
Novartis Investigative Site
Leipzig, 04277, Germany
Novartis Investigative Site
Loerrach, 79539, Germany
Novartis Investigative Site
Lübeck, 23538, Germany
Novartis Investigative Site
Mainz, 55131, Germany
Novartis Investigative Site
Marburg, 35037, Germany
Novartis Investigative Site
Marktredwitz, 95615, Germany
Novartis Investigative Site
Memmingen, 87700, Germany
Novartis Investigative Site
Minden, 32429, Germany
Novartis Investigative Site
Moers, 47441, Germany
Novartis Investigative Site
Münster, 48145, Germany
Novartis Investigative Site
Naunhof, 04683, Germany
Novartis Investigative Site
Neuruppin, 16816, Germany
Novartis Investigative Site
Neuss, 41462, Germany
Novartis Investigative Site
Neuss, 41464, Germany
Novartis Investigative Site
Nuremberg, 90419, Germany
Novartis Investigative Site
Nuremberg, 90449, Germany
Novartis Investigative Site
Offenbach, 63069, Germany
Novartis Investigative Site
Offenburg, 77654, Germany
Novartis Investigative Site
Oldenburg, 26121, Germany
Novartis Investigative Site
Osnabrück, 49076, Germany
Novartis Investigative Site
Passau, 94036, Germany
Novartis Investigative Site
Potsdam, 14467, Germany
Novartis Investigative Site
Ravensburg, 88214, Germany
Novartis Investigative Site
Regensburg, 93053, Germany
Novartis Investigative Site
Rheine, 48431, Germany
Novartis Investigative Site
Rodgau, 63110, Germany
Novartis Investigative Site
Rosenheim, 83022, Germany
Novartis Investigative Site
Rostock, 18059, Germany
Novartis Investigative Site
Rüsselsheim am Main, 65428, Germany
Novartis Investigative Site
Saarbrücken, 66113, Germany
Novartis Investigative Site
Saarlouis, 66740, Germany
Novartis Investigative Site
Salzgitter, 38226, Germany
Novartis Investigative Site
Schkeuditz, 04435, Germany
Novartis Investigative Site
Schorndorf, 73614, Germany
Novartis Investigative Site
Schwäbisch Hall, 74523, Germany
Novartis Investigative Site
Schweinfurt, 97422, Germany
Novartis Investigative Site
Soest, 59494, Germany
Novartis Investigative Site
Stade, 21680, Germany
Novartis Investigative Site
Stendal, 39576, Germany
Novartis Investigative Site
Stolberg, 52222, Germany
Novartis Investigative Site
Stuttgart, 70174, Germany
Novartis Investigative Site
Stuttgart, 70199, Germany
Novartis Investigative Site
Suhl, 98527, Germany
Novartis Investigative Site
Torgau, 04860, Germany
Novartis Investigative Site
Trier, 54290, Germany
Novartis Investigative Site
Tübingen, 72076, Germany
Novartis Investigative Site
Ulm, 89073, Germany
Novartis Investigative Site
Ulm, 89081, Germany
Novartis Investigative Site
Vechta, 49377, Germany
Novartis Investigative Site
Völklingen, 66333, Germany
Novartis Investigative Site
Weiden, 92637, Germany
Novartis Investigative Site
Weinheim, 69469, Germany
Novartis Investigative Site
Wetzlar, 35578, Germany
Novartis Investigative Site
Wiesbaden, 65189, Germany
Novartis Investigative Site
Wilhelmshaven, 26389, Germany
Novartis Investigative Site
Wolfsburg, 38440, Germany
Novartis Investigative Site
Worms, 67550, Germany
Novartis Investigative Site
Würselen, 52146, Germany
Novartis Investigative Site
Würzburg, 97080, Germany
Related Publications (1)
Decker T, Brucker C, Engel A, Fasching PA, Gohler T, Jackisch C, Janssen J, Kohler A, Ludtke-Heckenkamp K, Luftner D, Marme F, van Mackelenbergh M, Rautenberg B, Schmidt M, Weide R, Wimberger P, Kisseleff E, Pfister C, Roos C, Wilhelm N, Wockel A. Conditional progression-free survival in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with first-line ribociclib and endocrine therapy: real-world data from the RIBANNA study. ESMO Open. 2025 Jun;10(6):105105. doi: 10.1016/j.esmoop.2025.105105. Epub 2025 May 16.
PMID: 40381382RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Novartis Pharmaceuticals
Novartis Pharmaceuticals
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 29, 2023
First Posted
March 15, 2024
Study Start
October 9, 2017
Primary Completion
March 10, 2025
Study Completion
March 10, 2025
Last Updated
January 27, 2026
Record last verified: 2026-01
Data Sharing
- IPD Sharing
- Will not share